ASCO Journals have adopted a format-free submission policy (EZSubmit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, order of components, figure ...

Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma Anti–vascular endothelial growth factor therapy enhances PD-1 ...

Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment Because of a lack of evidence-based ...

Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors Patients who were 20 years or older, diagnosed in 2013-2019 with breast ...

Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group Treatment stratification in ALL ...

Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group In 467 consecutive patients with ALL ...

View all available purchase options and get full access to this article. Supported by Damon Runyon Foundation, V Foundation for Cancer Research, and Sabin Family Foundation (X.L.); NIH/NCI P30CA016672 ...

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 ...

Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML ...

Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022 Fig 1. Challenges in the management of advanced prostate cancer.

ASCO’s mission is to conquer cancer through research, education, and promotion of the highest quality patient care. We work toward this goal in part through the dissemination of high-quality, ...

Abbreviations: AFP, alpha-fetoprotein; CIK, cytokine-induced killer; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; HAIC, hepatic arterial infusion chemotherapy ...